These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 17509004)

  • 1. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese.
    Man CB; Kwan P; Baum L; Yu E; Lau KM; Cheng AS; Ng MH
    Epilepsia; 2007 May; 48(5):1015-8. PubMed ID: 17509004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variation in
    McCormack M; Gui H; Ingason A; Speed D; Wright GEB; Zhang EJ; Secolin R; Yasuda C; Kwok M; Wolking S; Becker F; Rau S; Avbersek A; Heggeli K; Leu C; Depondt C; Sills GJ; Marson AG; Auce P; Brodie MJ; Francis B; Johnson MR; Koeleman BPC; Striano P; Coppola A; Zara F; Kunz WS; Sander JW; Lerche H; Klein KM; Weckhuysen S; Krenn M; Gudmundsson LJ; Stefánsson K; Krause R; Shear N; Ross CJD; Delanty N; ; Pirmohamed M; Carleton BC; ; Cendes F; Lopes-Cendes I; Liao WP; O'Brien TJ; Sisodiya SM; ; Cherny S; Kwan P; Baum L; ; Cavalleri GL
    Neurology; 2018 Jan; 90(4):e332-e341. PubMed ID: 29288229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.
    McCormack M; Alfirevic A; Bourgeois S; Farrell JJ; Kasperavičiūtė D; Carrington M; Sills GJ; Marson T; Jia X; de Bakker PI; Chinthapalli K; Molokhia M; Johnson MR; O'Connor GD; Chaila E; Alhusaini S; Shianna KV; Radtke RA; Heinzen EL; Walley N; Pandolfo M; Pichler W; Park BK; Depondt C; Sisodiya SM; Goldstein DB; Deloukas P; Delanty N; Cavalleri GL; Pirmohamed M
    N Engl J Med; 2011 Mar; 364(12):1134-43. PubMed ID: 21428769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unraveling the genetic link: an umbrella review on HLA-B*15:02 and antiepileptic drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Tham KM; Yek JJL; Liu CWY
    Pharmacogenet Genomics; 2024 Jul; 34(5):154-165. PubMed ID: 38527170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Evaluation of HLA-B*15:02 Genotyping for Asian Australian Patients With Epilepsy.
    Gu Y; Shih STF; Geevasinga N; Chan L; Frew JW; Sebaratnam DF
    JAMA Dermatol; 2024 Jun; 160(6):631-640. PubMed ID: 38717780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is universal HLA-B*15:02 screening a cost-effective option in an ethnically diverse population? A case study of Malaysia.
    Chong HY; Mohamed Z; Tan LL; Wu DBC; Shabaruddin FH; Dahlui M; Apalasamy YD; Snyder SR; Williams MS; Hao J; Cavallari LH; Chaiyakunapruk N
    Br J Dermatol; 2017 Oct; 177(4):1102-1112. PubMed ID: 28346659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions.
    McCormack M; Urban TJ; Shianna KV; Walley N; Pandolfo M; Depondt C; Chaila E; O'Conner GD; Kasperavičiūtė D; Radtke RA; Heinzen EL; Sisodiya SM; Delanty N; Cavalleri GL
    Pharmacogenomics; 2012 Mar; 13(4):399-405. PubMed ID: 22379998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs.
    Manson LEN; Nijenhuis M; Soree B; de Boer-Veger NJ; Buunk AM; Houwink EJF; Risselada A; Rongen GAPJM; van Schaik RHN; Swen JJ; Touw DJ; van Westrhenen R; Deneer VHM; Guchelaar HJ
    Eur J Hum Genet; 2024 Aug; 32(8):903-911. PubMed ID: 38570725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics to prevent hypersensitivity reactions to antiepileptic drugs: is testing performed when indicated?
    Bui VL; Alvarez-Arango S; Stevenson JM
    Pharmacogenet Genomics; 2024 Jan; 34(1):16-19. PubMed ID: 37830946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of HLA-B*15:02 screening before treatment of epilepsy in Indonesia.
    Tanoto E; Khosama H; Jehosua S; Sekeon SAS; Karema W; Mawuntu AHP; Langi FFLG; Kheng Seang L
    Epilepsy Behav; 2024 Jun; 155():109787. PubMed ID: 38657484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics and Oxcarbazepine in Children and Adolescents: Beyond
    Stancil SL; Sandritter T; Strawn JR
    J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):61-66. PubMed ID: 38377523
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.
    Karnes JH; Rettie AE; Somogyi AA; Huddart R; Fohner AE; Formea CM; Ta Michael Lee M; Llerena A; Whirl-Carrillo M; Klein TE; Phillips EJ; Mintzer S; Gaedigk A; Caudle KE; Callaghan JT
    Clin Pharmacol Ther; 2021 Feb; 109(2):302-309. PubMed ID: 32779747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-B*53:01 Is a Significant Risk Factor of Liver Injury due to Phenytoin and Other Antiepileptic Drugs in African Americans.
    Nicoletti P; Dellinger A; Li YJ; Barnhart H; Phillips E; Chalasani N;
    Am J Gastroenterol; 2024 Jan; 119(1):200-202. PubMed ID: 37552102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular identification of HLA-B75 serotype markers by qPCR: A more inclusive pharmacogenetic approach before carbamazepine prescription.
    Jaruthamsophon K; Sangmanee P; Plong-On O; Charalsawadi C; Sukasem C; Hnoonual A
    Clin Transl Sci; 2024 Jun; 17(6):e13867. PubMed ID: 38894615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics in Asian Subpopulations and Impacts on Commonly Prescribed Medications.
    Lo C; Nguyen S; Yang C; Witt L; Wen A; Liao TV; Nguyen J; Lin B; Altman RB; Palaniappan L
    Clin Transl Sci; 2020 Sep; 13(5):861-870. PubMed ID: 32100936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Effects of HLA-B∗15:11 and HLA-A∗31:01 on Carbamazepine-Induced Cutaneous Adverse Reactions.
    Fukunaga K; Tsukagoshi E; Kurata M; Mizukawa Y; Niihara H; Morita E; Watanabe Y; Yamaguchi Y; Watanabe H; Nakajima S; Nomura T; Kabashima K; Tohyama M; Azukizawa H; Asada H; Hasegawa A; Hama N; Ozeki T; Mashimo Y; Sekine A; Matsunaga K; Tanaka Y; Nakamura R; Abe R; Mushiroda T; Saito Y
    J Invest Dermatol; 2024 Apr; 144(4):908-911.e7. PubMed ID: 37914023
    [No Abstract]   [Full Text] [Related]  

  • 17. A highlight on carbamazepine-induced adverse drug reactions in Saudi Arabia: a retrospective medical records-based study.
    Sukkarieh HH; Khokhar AA; Bustami RT; Karbani GA; Alturki FA; Alvi SN
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Nov; 396(11):3177-3182. PubMed ID: 37199768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of HLA-A∗11:01, HLA-B∗39:01, and HLA-B∗56:03 with salazosulfapyridine-induced cutaneous adverse drug reactions.
    Fukunaga K; Tsukagoshi E; Nakamura R; Matsunaga K; Ozeki T; Watanabe H; Hasegawa A; Hama N; Kurata M; Mizukawa Y; Watanabe Y; Yamaguchi Y; Niihara H; Morita E; Asada H; Abe R; Saito Y; Mushiroda T
    J Allergy Clin Immunol Pract; 2024 May; 12(5):1355-1358.e3. PubMed ID: 38613561
    [No Abstract]   [Full Text] [Related]  

  • 19. [HUMAN LEUKOCYTE ANTIGEN (HLA) GENES ASSOCIATED WITH DRUG ERUPTIONS AND OTHER DRUG ALLERGIC SIDE EFFECTS].
    Mushiroda T
    Arerugi; 2024; 73(4):307-312. PubMed ID: 38880628
    [No Abstract]   [Full Text] [Related]  

  • 20. Cutaneous adverse effects of antiepileptic drugs.
    Zgolli F; Aouinti I; Charfi O; Kaabi W; Hamza I; Daghfous R; Kastalli S; Lakhoua G; Aidli SE
    Therapie; 2024; 79(4):453-459. PubMed ID: 37865562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.